All in all, high investments, a hike in allowed returns as of 2026, and a low comparison basis in 2024 will underpin a high earnings growth. On the other hand, the group cut its dividend to EUR 0.8 ...

ResMed has a minority stake in Nyxoah who are developing a neurostimulation implant to treat OSA. Although we see little near-term risk from this therapy due to the higher cost and invasive surgery ...

As Artificial Intelligence (AI) technology advances, the need for efficient and scalable inference solutions has grown ...